A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a fourth-generation specific chimeric antigen receptor (4SCAR) specific for CD44 variant domain 6 (CD44v6), with potential immunomodulating and antineoplastic activities. Upon administration, CD44v6-specific CAR T-cells specifically recognize and kill CD44v6-expressing tumor cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types. CD44v6, the isoform containing the variant domain 6 of CD44 gene, plays a key role in tumor cell invasion, proliferation and metastasis.